Introduction: The objective of this study was to
INTRODUCTION
The International Diabetes Federation estimates that there are 56.3 million adults with diabetes, representing 8.5% of European adults [1] . Type 2 diabetes (T2D) constitutes 85-95% of all diabetes, and the incidence/prevalence continues to increase due in part to obesity, physical inactivity, and poor diet. This has substantial cost implications to healthcare systems and society [1] . Upon diagnosis of T2D, patients are often required to engage in healthy eating, weight control, and increased physical activity to improve glycemic sensitivity/control [2] . However, most patients will require drug therapy, with metformin monotherapy generally preferred as initial pharmacological treatment. GLP-1 RAs mimic endogenous GLP-1, stimulating insulin release from the pancreas and suppressing glucagon secretion [2] . GLP-1 RAs are associated with high glycemic efficacy, weight loss and low risk of hypoglycemia, but with some risk of gastrointestinal side effects. While concerns of an association with pancreatic disease exist, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have agreed that a causal association is inconsistent with the current data [3] . There are five EMA approved GLP-1 Daily doses, injection frequencies and injection time related to meals of current GLP-1 RA therapies are variable. For example, the initial dose of exBID is 5 lg injected under the skin (subcutaneously) twice daily, 60 min before two major meals with at least 6 h in between. The dose can be increased to 10 lg twice daily after 1 month of therapy [4] . LIRA is administered once daily independent of meals and should be initiated with a dose of 0.6 mg once daily for the first week, followed by a dose increase to 1.2 mg once daily [5] . If the 1.2 mg dose does not result in acceptable glycemic control, the dose may be increased to 1.8 mg after at least 1 week, although the EMA [6] and the National Institute for Health and Care Excellence (NICE) [7] state that the available evidence suggests only marginal benefit of this escalation on glycemic control. ExQW is administered once per week independent of meals at a dose of 2.0 mg [8] . While the ADA/ EASD recommend GLP-1 RA therapy in secondor third-line therapy [2] , some European Union (EU) health care authorities, including the United Kingdom (UK) [7] , the Netherlands (NE) [9] , Sweden (SE) [10] , and Belgium (BE) [11] , generally recommend GLP-1 RAs as a third-line therapy, often restricted to certain populations (obese, intolerant to other therapies, etc.).
Only a few studies have compared treatment patterns or variable dosing between exBID and LIRA [12] [13] [14] . Little is known about treatment patterns among GLP-1 RA therapy users in the real-world setting, particularly for exQW, or average patient dosing given variability in dosing for exBID and LIRA. The primary objective of this analysis was to evaluate treatment patterns among T2D GLP-1 RA therapy initiators, specifically persistence with the index therapy and treatment modification [discontinuation, switch, stop (a composite outcome of either discontinuation or switch)
or augmentation]. Secondary objectives included evaluating average daily dose (ADD) of the therapy and the patient characteristics associated with risk of stopping therapy. These outcomes were evaluated using available databases containing prescription data in Germany (GE), the UK, France (FR), NE, BE, and SE. When this study was conducted, exBID, exQW, and LIRA were the only approved GLP-1 RAs; therefore, these therapies comprise the cohorts of this study.
METHODS
A retrospective cohort analysis was conducted using eight databases in six European countries (GE, the UK, FR, NE, BE, and SE). This study involved a retrospective cohort analysis using eight databases, and the analysis does not contain studies with human or animal subjects performed by any of the authors. Research ethics approval was received from the regional Ethics Review Board in Stockholm in order to conduct the Swedish analysis. Ethics approval was not required in the other countries.
Data Sources

Electronic Medical Records
The 
Patient Selection
Patients were first identified based on a prescription for the therapy of interest (exBID, exQW, or LIRA) within the selection window (Table 1) , which varied by country and was adjusted for exQW given its more recent launch (June 2011). The first prescription for a therapy of interest within the selection window was termed the 'index therapy' and the date was termed the 'index date'. Patients were followed through the end of continuous eligibility (CE;
i.e., visibility) or study end date, whichever occurred first.
Adult patients (C18 years on the index date)
were identified as eligible if they met the following inclusion/exclusion criteria: (1) evidence of T2D [no evidence of type 1 diabetes (T1D); see Table 1 for database-specific criteria], (2) C180-day CE pre-index, (3) C360-day CE post-index (C180-day post-index for exQW patients only) within the database (see Table 1 for database-specific CE criteria), (4) naïve to the initiated therapy class with no prescription for any GLP- Continuous Eligibility Criteria/Follow-up Germany/ France EMR Based on patient activity (physician visit or written prescription), and additionally in France, reporting physician required to report consistently throughout the study window; followed until the last evidence of activity within the study period UK EMR Based on patient registration date; followed until study end date or de-registration date LRx Based on patient prescription activity and all pharmacies visited by patient eligible for the full study time frame; followed until the end of study window (exception of UK LRx; aggregate-level analysis)
Sweden Based on patient prescription activity; followed until first of either end of study period or death
Evidence of T2D (no evidence of T1D) EMR (diagnoses available) Evidence of T2D was required as either (a) ICD-10 diagnosis codes of diabetes, E10-E14, in the 180-day pre-index (termed the preindex period) up to 60 days post-index or (b) at least C1 OAM class and no diagnosis for polycystic ovarian syndrome (ICD-10: Average ADDs over calendar months were summarized to provide both a yearly and overall ADD. An average weekly dose (AWD) was calculated for exQW by multiplying the ADD by 7. Prescriptions received within 14 days of a previous prescription were excluded to avoid overestimating ADD due to duplicate prescriptions or ambiguous up-titration with an exception for the prescription following the index therapy (i.e., the second prescription) if the gap between the second and third prescription was equal to the expected duration of the prescribed therapy. ADD in the UK LRx (aggregated data) was calculated as follows: total units of drug prescribed in a month were summed and divided by the total number of patients with a prescription in that month; then divided by the number of days in that month. This does not account for multiple prescriptions prescribed for a patient in a month which could result in over-inflation of ADD estimates. For yearly and overall ADD/ AWD calculations, calendar months with less than 30 patients were trimmed.
A wide range of ADDs were expected, due to variability in gaps between consecutive prescriptions [13] . Given overall ADD sensitivity to small gaps/overlaps in available prescriptions, we grouped ranges of ADD values in categories consistent with labeled use and dispensed doses to calculate titration outcomes. On-label up-titration was assessed as a separate 24.7
Number of antihyperglycemic therapy classes used in the 180-day pre-index period Mean Table 2 continued was assessed using Kaplan-Meier (KM) analysis.
For the EMR cohorts, Cox proportional hazards models (PHMs) were developed to assess risk of stopping the index therapy. Statistical and descriptive analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA).
A P value \0.05 was considered statistically significant.
RESULTS
Patient Sample
After application of the inclusion/exclusion criteria, Patient-level analysis was not possible with the UK LRx due to privacy legislation; only age group at index and gender were available and are described in the text N/a data not applicable or unavailable, s data suppressed in Sweden due to patient count less than 10 in compliance with Swedish privacy legislation 
DPP-IV
Treatment Patterns
Across databases, the proportion of patients persistent at 180 days was higher among LIRA and exQW patients compared to exBID ( 
Cox Proportional Hazards Models for Risk of Stopping
Type of index therapy was significantly associated with risk of stopping in all EMR countries, with LIRA associated with a lower risk of stopping compared to exBID (Table 4 ). In GE, compared to exBID, exQW was associated with a 54% lower risk while LIRA was associated with a 31% lower risk (both P\0.001). In UK, compared to exBID, LIRA was associated with a 28% lower risk (P\0.001). In FR, compared to exBID, LIRA was associated with a 38% lower risk (P = 0.002). In both GE and UK, concomitant use of a biguanide was associated with a lower risk of stopping the index therapy compared to no biguanide use. In GE, other significant predictors for stop included male gender, GP physician type, depression and nonneuropathic pain in the pre-index and no CV disease and concomitant insulin use. It is important to note the availability of physician type in GE only and the different sample sizes, which may impact model findings.
Average Daily Dose
ADD by calendar year (year of prescription) and overall (over the entire follow-up period) is reported in recommended by the EMA [6] and NICE [7] , suggesting that on average, many patients are using and benefitting from the higher dose.
Some differences between treatment patterns by index therapy were observed between databases in GE (EMR and LRx), including the proportion stopping therapy; it is important to consider the different populations (physician EMR records vs. filled pharmacy claims) and variable followup periods, as well as the much higher sample size for LRx. Overall ADD results in GE EMR compared to GE LRx were similar (exBID: 17.65, 17.70 lg; exQW: 0.31, 0.29 mg; LIRA: 1.44, 1.40 mg, respectively). The ADD was higher as calculated in the UK LRx for all therapies compared to the UK EMR, likely related to over-estimation with the aggregate-level analysis. It is important to note that the (1) time between therapy class prescriptions in pre-and post-index of 120 days or less, with overlap on index or (2) Mean ADD was 16.7 lg for exBID and 1.43 mg for LIRA, while in our GE EMR analysis, we found a higher ADD for exBID, 17.7 lg, and a similar ADD for LIRA, 1.44 mg. In addition, based on Cox PHM estimates in the Miller et al. 
